Halkes PH - Search Results

1

Interpretation of ESPRIT in the FASTER trial.

Algra A, van Gijn J, Halkes PH, Kappelle LJ, Koudstaal PJ; ESPRIT Study Group. Algra A, et al. Among authors: halkes ph. Lancet Neurol. 2008 Mar;7(3):198-9; author reply 199. doi: 10.1016/S1474-4422(08)70030-9. Lancet Neurol. 2008. PMID: 18275919 No abstract available.

2

Oral anticoagulation in secondary prevention after cerebral ischemia of arterial origin.

Halkes PH; ESPRIT Study Group. Halkes PH, et al. Stroke. 2005 May;36(5):933. doi: 10.1161/01.str.0000163821.57159.e0. Stroke. 2005. PMID: 15867167 No abstract available.

3

Classification of cause of death after stroke in clinical research.

Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Halkes PH, et al. Stroke. 2006 Jun;37(6):1521-4. doi: 10.1161/01.STR.0000222978.96083.d9. Epub 2006 May 4. Stroke. 2006. PMID: 16675732

4

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.

ESPRIT Study Group; Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. ESPRIT Study Group, et al. Among authors: halkes ph. Lancet. 2006 May 20;367(9523):1665-73. doi: 10.1016/S0140-6736(06)68734-5. Lancet. 2006. PMID: 16714187 Clinical Trial.

5

Large subcortical infarcts: clinical features, risk factors, and long-term prognosis compared with cortical and small deep infarcts.

Halkes PH, Kappelle LJ, van Gijn J, van Wijk I, Koudstaal PJ, Algra A. Halkes PH, et al. Stroke. 2006 Jul;37(7):1828-32. doi: 10.1161/01.STR.0000226993.88307.ff. Epub 2006 Jun 1. Stroke. 2006. PMID: 16741175

6

Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.

ESPRIT Study Group; Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. ESPRIT Study Group, et al. Among authors: halkes ph. Lancet Neurol. 2007 Feb;6(2):115-24. doi: 10.1016/S1474-4422(06)70685-8. Lancet Neurol. 2007. PMID: 17239798 Clinical Trial.

7

Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient?

Halkes PH, Algra A. Halkes PH, et al. Cerebrovasc Dis. 2007;24 Suppl 1:107-11. doi: 10.1159/000107385. Epub 2007 Nov 1. Cerebrovasc Dis. 2007. PMID: 17971645 Review.

8

Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.

Halkes PH, Gray LJ, Bath PM, Diener HC, Guiraud-Chaumeil B, Yatsu FM, Algra A. Halkes PH, et al. J Neurol Neurosurg Psychiatry. 2008 Nov;79(11):1218-23. doi: 10.1136/jnnp.2008.143875. Epub 2008 Jun 5. J Neurol Neurosurg Psychiatry. 2008. PMID: 18535024

9

[Thromboprophylaxis for cerebrovascular disorders: acetylsalicylic acid remains the cornerstone].

Algra A, De Schryver EL, Halkes PH. Algra A, et al. Among authors: halkes ph. Ned Tijdschr Geneeskd. 2008 May 17;152(20):1179; author reply 1180. Ned Tijdschr Geneeskd. 2008. PMID: 18549147 Dutch. No abstract available.

10

Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin.

Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A; European/Australasian Stroke Prevention in Reversible Ischaemia Trial Study Group. Halkes PH, et al. J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):437-9. doi: 10.1136/jnnp.2008.147918. J Neurol Neurosurg Psychiatry. 2009. PMID: 19289481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters